You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesmopressin
Accession NumberDB00035  (BTD00112, BTD00061, BIOD00112, BIOD00061)
TypeSmall Molecule
GroupsApproved
DescriptionDesmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.
Structure
Thumb
Synonyms
1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
1-deamino-8-D-arginine vasopressin
1-Desamino-8-D-arginine vasopressin
DDAVP
Desmopresina
Desmopressin
Desmopressine
Desmopressinum
Minirin
Stimate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DdavpTablet.1 mg/1OralFerring Pharmaceuticals Inc.1995-09-06Not applicableUs
DdavpSolution4 ug/mLIntravenousSanofi Aventis U.S. Llc1984-03-30Not applicableUs
DdavpTablet.2 mg/1OralFerring Pharmaceuticals Inc.1995-09-06Not applicableUs
DdavpTablet.1 mg/1OralSanofi Aventis U.S. Llc1995-09-06Not applicableUs
DdavpInjection4 ug/mLIntravenousFerring Pharmaceuticals Inc.1984-03-30Not applicableUs
DdavpSolution.1 mg/mLNasalSanofi Aventis U.S. Llc1978-02-21Not applicableUs
DdavpTablet.2 mg/1OralSanofi Aventis U.S. Llc1995-09-06Not applicableUs
DdavpInjection4 ug/mLIntravenousFerring Pharmaceuticals Inc.1984-03-30Not applicableUs
DdavpSpray.1 ug/mLNasalFerring Pharmaceuticals Inc.1978-02-21Not applicableUs
DdavpSpray.1 ug/mLNasalFerring Pharmaceuticals Inc.1978-02-21Not applicableUs
Ddavp Inj 4mcg/mlLiquid4 mcgIntramuscular; Intravenous; SubcutaneousFerring Inc1993-12-31Not applicableCanada
Ddavp MeltTablet, orally disintegrating240 mcgSublingualFerring Inc2009-05-05Not applicableCanada
Ddavp MeltTablet, orally disintegrating60 mcgSublingualFerring Inc2006-11-02Not applicableCanada
Ddavp MeltTablet, orally disintegrating120 mcgSublingualFerring Inc2006-11-02Not applicableCanada
Ddavp Rhinal TubeSolution.1 mg/mLNasalSanofi Aventis U.S. Llc1978-02-21Not applicableUs
Ddavp RhinyleSolution0.1 mgNasalFerring Inc1992-12-31Not applicableCanada
Ddavp SprayAerosol, metered10 mcgNasalFerring Inc1989-12-31Not applicableCanada
Ddavp Tablets 0.1mgTablet0.1 mgOralFerring Inc1995-12-31Not applicableCanada
Ddavp Tablets 0.2mgTablet0.2 mgOralFerring Inc1995-12-31Not applicableCanada
DesmopressinTablet0.1 mgOralMeliapharm Inc2011-07-272014-06-25Canada
DesmopressinTablet0.2 mgOralMeliapharm Inc2011-07-272014-06-25Canada
Desmopressin AcetateTablet.1 mg/1OralAmring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin AcetateSolution4 ug/mLIntravenousAmring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin AcetateSolution4 ug/mLIntravenousFerring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralAmring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin AcetateSolution4 ug/mLIntravenousAmring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralFerring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin AcetateSolution.1 mg/mLNasalFerring Pharmaceuticals Inc.1999-08-10Not applicableUs
Desmopressin AcetateSpray10 ug/.1mLNasalAmring Pharmaceuticals, Inc.2016-03-01Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralFerring Pharmaceuticals Inc.2008-05-05Not applicableUs
Desmopressin AcetateSolution4 ug/mLIntravenousFerring Pharmaceuticals Inc.1999-10-26Not applicableUs
Desmopressin AcetateSpray10 ug/.1mLNasalPrasco Laboratories2014-01-01Not applicableUs
Desmopressin SpraySpray, metered10 mcgNasalAa Pharma Inc2000-08-18Not applicableCanada
Desmopressin TabletsTablet0.1 mgOralRainbow Pharmaceuticals Inc2005-02-182012-08-03Canada
Desmopressin TabletsTablet0.2 mgOralRainbow Pharmaceuticals Inc2005-02-182012-08-03Canada
MinirinAerosol, metered10 mcgNasalFerring Inc2000-08-212005-08-02Canada
MinirinTablet0.1 mgOralFerring Inc2003-01-152015-07-22Canada
NocdurnaTablet, orally disintegrating25 mcgSublingualFerring Inc2013-07-31Not applicableCanada
NocdurnaTablet, orally disintegrating50 mcgSublingualFerring Inc2014-11-17Not applicableCanada
Nu-desmopressin SpraySpray, metered0.1 gNasalNu Pharm IncNot applicableNot applicableCanada
Octostim Liq Inj. 15mcg/mlLiquid15 mcgIntravenous; SubcutaneousFerring Inc1995-12-31Not applicableCanada
Octostim SpraySpray150 mcgNasalFerring Inc1998-12-01Not applicableCanada
PMS-desmopressinTablet0.2 mgOralPharmascience Inc2008-01-23Not applicableCanada
PMS-desmopressinTablet0.1 mgOralPharmascience Inc2008-01-23Not applicableCanada
StimateSpray, metered1.5 mg/mLNasalCSL Behring LLC2011-09-16Not applicableUs
Teva-desmopressinTablet0.1 mgOralTeva Canada Limited2007-07-16Not applicableCanada
Teva-desmopressinTablet0.2 mgOralTeva Canada Limited2007-07-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-desmopressinTablet0.1 mgOralApotex Inc2007-01-31Not applicableCanada
Apo-desmopressinTablet0.2 mgOralApotex Inc2007-01-31Not applicableCanada
Desmopressin AcetateTablet.2 mg/1Oralbryant ranch prepack2011-08-15Not applicableUs
Desmopressin AcetateInjection4 ug/mLIntravenousTeva Parenteral Medicines, Inc.1997-11-01Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralApotex Corp.2006-03-07Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralAmerican Health Packaging2010-01-122015-12-29Us
Desmopressin AcetateTablet.1 mg/1OralTeva Pharmaceuticals USA Inc2006-01-27Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralAv Pak2013-07-24Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralAmerican Health Packaging2012-10-08Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralActavis Pharma, Inc.2011-08-15Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralAmerican Health Packaging2015-09-15Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralImpax Generics2006-01-27Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralBlue Point Laboratories2014-02-27Not applicableUs
Desmopressin AcetateSolution.1 mg/mLNasalBauch & Lomb Incorporated1999-01-25Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralApotex Corp.2006-03-07Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralAmerican Health Packaging2010-01-122015-12-29Us
Desmopressin AcetateTablet.2 mg/1OralTeva Pharmaceuticals USA Inc2006-01-27Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralMylan Institutional Inc.2007-12-26Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralCarilion Materials Management2006-01-27Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-17Not applicableUs
Desmopressin AcetateSolution.1 mg/mLNasalSun Pharmaceutical Industries Limited2012-04-14Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralImpax Generics2006-01-27Not applicableUs
Desmopressin AcetateSolution.1 mg/mLNasalSun Pharma Global FZE2013-12-24Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralBlue Point Laboratories2014-02-27Not applicableUs
Desmopressin AcetateInjection, solution4 ug/mLIntravenous; SubcutaneousHospira, Inc.2000-08-28Not applicableUs
Desmopressin AcetateSpray10 ug/1NasalApotex Corp.2005-01-27Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2015-05-28Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralPhysicians Total Care, Inc.2007-07-19Not applicableUs
Desmopressin AcetateInjection, solution4 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2013-01-30Not applicableUs
Desmopressin AcetateInjection4 ug/mLIntravenousTeva Parenteral Medicines, Inc.1997-11-01Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralAv Pak2013-07-24Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralAmerican Health Packaging2012-10-08Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralActavis Pharma, Inc.2011-08-15Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralAmerican Health Packaging2015-09-15Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2015-05-28Not applicableUs
Desmopressin AcetateSolution.1 mg/mLNasalPhysicians Total Care, Inc.2006-05-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdiuretinFerring
DesmoMeltFerring
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Desmopressin acetate
Thumb
  • InChI Key: MLSVJHOYXJGGTR-IFHOVBQLSA-N
  • Monoisotopic Mass: 1128.448084334
  • Average Mass: 1129.269
DBSALT000044
Desmopressin acetate trihydrate
ThumbNot applicableDBSALT001154
Categories
UNIIENR1LLB0FP
CAS number16679-58-6
WeightAverage: 1069.217
Monoisotopic: 1068.426954962
Chemical FormulaC46H64N14O12S2
InChI KeyNFLWUMRGJYTJIN-NXBWRCJVSA-N
InChI
InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide
SMILES
NC(=O)CC[C@@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
Pharmacology
IndicationOral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia.
Structured Indications
PharmacodynamicsDesmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand’s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting.
Mechanism of actionDesmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Vasopressin V2 receptorProteinyes
agonist
HumanP30518 details
Vasopressin V1a receptorProteinyesNot AvailableHumanP37288 details
Vasopressin V1b receptorProteinyesNot AvailableHumanP47901 details
Related Articles
AbsorptionMinimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa.
Volume of distributionNot Available
Protein binding50%
Metabolism

Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes.

Route of eliminationNot Available
Half lifeOral t1/2=1.5-2.5 hours. Intranasal t1/2=3.3-3.5 hours. IV t1/2 is biphasic: initial t1/2=7.8 minutes, terminal t1/2=0.4-4 hours.
ClearanceNot Available
ToxicityOverdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Desmopressin.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.Experimental, Illicit
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.Approved, Investigational
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desmopressin.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.Experimental, Illicit, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.Illicit, Vet Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.Approved, Illicit
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Desmopressin.Investigational
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.Investigational
DemeclocyclineThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.Approved, Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.Approved, Illicit
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Desmopressin.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Desmopressin.Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.Approved, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.Approved, Illicit
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.Illicit, Vet Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Desmopressin.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.Approved, Illicit, Investigational, Vet Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin.Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.Approved, Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.Approved, Illicit
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Desmopressin.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.Approved, Illicit
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.Investigational, Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.Withdrawn
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.Approved
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.Investigational
LithiumThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.Illicit
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Desmopressin.Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.Experimental, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.Approved, Investigational
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.Approved, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.Approved
TolvaptanThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desmopressin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.Investigational, Withdrawn
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, “High purity desmopressin produced in large single batches.” U.S. Patent US5674850, issued November, 1991.

US5674850
General References
  1. Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629 ]
External Links
ATC CodesH01BA02
AHFS Codes
  • 68:28.00
PDB EntriesNot Available
FDA labelDownload (90.1 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7979
Blood Brain Barrier-0.8866
Caco-2 permeable-0.7612
P-glycoprotein substrateSubstrate0.8242
P-glycoprotein inhibitor INon-inhibitor0.7864
P-glycoprotein inhibitor IINon-inhibitor0.9237
Renal organic cation transporterNon-inhibitor0.5915
CYP450 2C9 substrateNon-substrate0.7833
CYP450 2D6 substrateNon-substrate0.7901
CYP450 3A4 substrateNon-substrate0.5497
CYP450 1A2 substrateNon-inhibitor0.8383
CYP450 2C9 inhibitorNon-inhibitor0.7906
CYP450 2D6 inhibitorNon-inhibitor0.8735
CYP450 2C19 inhibitorNon-inhibitor0.765
CYP450 3A4 inhibitorNon-inhibitor0.7663
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9331
Ames testNon AMES toxic0.6679
CarcinogenicityNon-carcinogens0.8428
BiodegradationNot ready biodegradable0.9445
Rat acute toxicity2.7183 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.83
hERG inhibition (predictor II)Inhibitor0.6036
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Ferring pharmaceuticals inc
  • Bausch and lomb pharmaceuticals inc
  • Apotex inc richmond hill
  • Csl behring llc
  • Apotex inc etobicoke site
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous4 ug/mL
SprayNasal.1 ug/mL
TabletOral.1 mg/1
TabletOral.2 mg/1
LiquidIntramuscular; Intravenous; Subcutaneous4 mcg
Tablet, orally disintegratingSublingual120 mcg
Tablet, orally disintegratingSublingual240 mcg
Tablet, orally disintegratingSublingual60 mcg
SolutionNasal.1 mg/mL
SolutionNasal0.1 mg
Aerosol, meteredNasal10 mcg
TabletOral0.1 mg
TabletOral0.2 mg
InjectionIntravenous4 ug/mL
Injection, solutionIntravenous; Subcutaneous4 ug/mL
SprayNasal10 ug/.1mL
SprayNasal10 ug/1
Spray, meteredNasal10 mcg
Tablet, orally disintegratingSublingual25 mcg
Tablet, orally disintegratingSublingual50 mcg
Spray, meteredNasal0.1 g
LiquidIntravenous; Subcutaneous15 mcg
SprayNasal150 mcg
Spray, meteredNasal1.5 mg/mL
Prices
Unit descriptionCostUnit
Stimate 1.5 mg/ml nasal spray334.2USD ml
Ddavp 0.01% nasal spray50.76USD ml
Ddavp 4 mcg/ml ampul43.27USD ml
Desmopressin 0.1 mg/ml spray39.6USD ml
Ddavp 0.1 mg/ml Solution21.26USD ml
Octostim 150 mcg/dose Metered Dose Spray17.39USD dose
Ddavp 4 mcg/ml11.33USD ml
Desmopressin ac 4 mcg/ml amp7.28USD ml
Desmopressin ac 4 mcg/ml vial7.08USD ml
Ddavp 0.2 mg tablet6.43USD tablet
Ddavp 0.1 mg tablet4.47USD tablet
Desmopressin acetate 0.2 mg tablet4.44USD tablet
Desmopressin acetate 0.1 mg tablet3.08USD tablet
Ddavp 0.2 mg Tablet2.98USD tablet
Ddavp 10 mcg/dose Metered Dose Spray2.13USD dose
Apo-Desmopressin 0.2 mg Tablet1.67USD tablet
Novo-Desmopressin 0.2 mg Tablet1.67USD tablet
Pms-Desmopressin 0.2 mg Tablet1.67USD tablet
Ddavp 0.1 mg Tablet1.49USD tablet
Apo-Desmopressin 10 mcg/dose Metered Dose Spray1.48USD dose
Apo-Desmopressin 0.1 mg Tablet0.83USD tablet
Novo-Desmopressin 0.1 mg Tablet0.83USD tablet
Pms-Desmopressin 0.1 mg Tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2484724 No2007-01-162023-05-07Canada
CA2486833 No2005-08-022024-04-30Canada
US5500413 No1993-06-292013-06-29Us
US7022340 No2003-04-302023-04-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP-1ALOGPS
logP-6.1ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.5ChemAxon
pKa (Strongest Basic)11.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area435.41 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity279.78 m3·mol-1ChemAxon
Polarizability106.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentCyclic peptides
Alternative Parents
Substituents
  • Cyclic alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Macrolactam
  • Alpha-amino acid amide
  • N-substituted-alpha-amino acid
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • N-acylpyrrolidine
  • Phenol
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Primary carboxylic acid amide
  • Organic disulfide
  • Lactam
  • Guanidine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboximidamide
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name:
AVPR2
Uniprot ID:
P30518
Molecular Weight:
40278.57 Da
References
  1. Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325 ]
  2. Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.
Gene Name:
AVPR1A
Uniprot ID:
P37288
Molecular Weight:
46799.105 Da
References
  1. Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046 ]
  2. Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321 ]
  3. Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254 ]
  4. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name:
AVPR1B
Uniprot ID:
P47901
Molecular Weight:
46970.345 Da
References
  1. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460 ]
  2. Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638 ]
  3. Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23